๊ฐ€์ž… ํ›„ ์ดˆ๋Œ€ ๋งํฌ๋ฅผ ๊ณต์œ ํ•˜๋ฉด ๋™์˜์ƒ ์žฌ์ƒ ๋ฐ ์ดˆ๋Œ€ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

Marc Hilmi
@MarcHilmi
๐Ÿ‡ซ๐Ÿ‡ท ๐Ÿ‡บ๐Ÿ‡ธ GI oncologist MD PhD #PancreaticCancer# #Bioinformatics# #ImageAnalysis# #DigitalPathology# #SingleCell# #TCRSeq# #SpatialTranscriptomics# #Microbiota#
๊ฐ€์ž… September 2021
172 ํŒ”๋กœ์ž‰ ์ค‘    202 ํŒฌ
Grateful to present 3 posters at #ESMO2026# in Madrid! ๐Ÿ‡ช๐Ÿ‡ธ 1. Pathogenic germline ATM alterations define a distinct pancreatic cancer subtype with improved survival, less liver metastases and reduced KRAS signaling. @CentralParkWMD @EileenMOReilly @ciacobu @CpcrMsk 2. POSTN+ fibroblasts identify an aggressive tumor microenvironment and poorer survival in pancreatic cancer (#PRODIGE24#). @RemyNicolle @cros_jerome 3. Early CT-derived body composition changes predict survival in biliary tract cancer patients receiving immunotherapy, independently of radiological progression, CA19-9, ECOG PS, and weight loss (#PRODIGE57#). @DelayeMatthieu Grateful to all collaborators at @MSKCancerCenter, @institut_curie, and GERCOR/PRODIGE! #PancreaticCancer# #GIOncology#
๋” ๋ณด๊ธฐ